

Switch to BIC-TAF-FTC or DTG + TAF-FTC in Adults with Virologic Suppression

**GS-380-4030**

# Switch to BIC-TAF-FTC or DTG + TAF-FTC in Adults with Virologic Suppression

## GS-380-4030: Design

- **Background**

- Randomized, double-blind, switch study comparing the efficacy of switching adults with viral suppression (with or without documented or suspected NRTI resistance) taking DTG plus TAF-FTC or TDF-FTC to BIC-TAF-FTC versus DTG plus TAF-FTC

- **Inclusion Criteria**

- Age  $\geq 18$  years
- HIV RNA  $< 50$  copies/mL for 3 months if no resistance
- HIV RNA  $< 50$  copies/mL for 6 months if NRTI resistance
- Taking stable regimen of DTG plus TDF-FTC or TAF-FTC
- eGFR  $\geq 30$  mL/min
- Chronic HBV and HCV infection permitted
- Documented or suspected NRTI resistance permitted
- Excluded if integrase resistance or virologic failure on INSTI

**Bictegravir-TAF-FTC**

(n = 284)

**Dolutegravir + TAF-FTC**


(n = 281)

# Switch to BIC-TAF-FTC or DTG + TAF-FTC in Adults with Virologic Suppression GS-380-4030: Baseline Characteristics

| Study GS-380-4030 Baseline Participant Demographics & Clinical Characteristics |                          |                            |
|--|--------------------------|----------------------------|
| Baseline Characteristic  | BIC-TAF-FTC<br>(n = 284) | DTG + TAF-FTC<br>(n = 281) |
| Age, years, median (range)   | 51 (22-79)               | 50 (20-79)                 |
| Women, n (%)   | 39 (14%)                 | 41 (15%)                   |
| Black, n (%)   | 68 (24%)                 | 61 (22%)                   |
| Hispanic or Latino, n (%)  | 61 (22%)                 | 49 (18%)                   |
| CD4 cell count, cells/ $\mu$ L, median (IQR)                                   | 659 (486-885)            | 642 (462-791)              |
| TAF-FTC NRTI backbone, n (%)   | 194 (68%)                | 195 (69%)                  |
| K65R/E/N or $\geq$ 3 TAMs mutation(s), n (%)                                   | 16 (6%)                  | 14 (5%)                    |
| Any other pattern of NRTI mutation(s), n (%)                                   | 55 (19%)                 | 53 (19%)                   |
| No NRTI mutation, n (%)  | 213 (75%)                | 214 (76%)                  |

# Switch to BIC-TAF-FTC or DTG + TAF-FTC in Adults with Virologic Suppression GS-380-4030: Results

## Virologic Outcome at Week 48



Primary outcome of HIV RNA  $\geq 50$  copies/mL at 48 weeks: 0.4% BIC-TAF-FTC arm; 1.1% DTG + TAF-FTC arm

# Switch to BIC-TAF-FTC or DTG + TAF-FTC in Adults with Virologic Suppression

## GS-380-4030: Conclusions

**Interpretation:** “The single-tablet regimen B/F/TAF is a safe, effective option for people virologically suppressed on DTG plus either F/TDF or F/TAF, including in individuals with preexisting resistance to NRTIs.”

# Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [HRSA.gov](http://HRSA.gov). This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

